Literature DB >> 22399752

Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo.

Emanuela Colla1, Poul H Jensen, Olga Pletnikova, Juan C Troncoso, Charles Glabe, Michael K Lee.   

Abstract

In Parkinson's disease (PD) and other α-synucleinopathies, prefibrillar α-synuclein (αS) oligomer is implicated in the pathogenesis. However, toxic αS oligomers observed using in vitro systems are not generally seen to be associated with α-synucleinopathy in vivo. Thus, the pathologic significance of αS oligomers to αS neurotoxicity is unknown. Herein, we show that, αS that accumulate within endoplasmic reticulum (ER)/microsome forms toxic oligomers in mouse and human brain with the α-synucleinopathy. In the mouse model of α-synucleinopathy, αS oligomers initially form before the onset of disease and continue to accumulate with the disease progression. Significantly, treatment of αS transgenic mice with Salubrinal, an anti-ER stress compound that delays the onset of disease, reduces ER accumulation of αS oligomers. These results indicate that αS oligomers with toxic conformation accumulate in ER, and αS oligomer-dependent ER stress is pathologically relevant for PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22399752      PMCID: PMC3548448          DOI: 10.1523/JNEUROSCI.5368-11.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  26 in total

1.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

2.  Proteasomal inhibition by alpha-synuclein filaments and oligomers.

Authors:  Evo Lindersson; Rasmus Beedholm; Peter Højrup; Torben Moos; WeiPing Gai; Klavs B Hendil; Poul H Jensen
Journal:  J Biol Chem       Date:  2004-01-07       Impact factor: 5.157

3.  Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion.

Authors:  Nirmal Gosavi; He-Jin Lee; Jun Sung Lee; Smita Patel; Seung-Jae Lee
Journal:  J Biol Chem       Date:  2002-09-25       Impact factor: 5.157

Review 4.  Genetic clues to the pathogenesis of Parkinson's disease.

Authors:  Miquel Vila; Serge Przedborski
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

5.  Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.

Authors:  Wenxue Li; Neva West; Emanuela Colla; Olga Pletnikova; Juan C Troncoso; Laura Marsh; Ted M Dawson; Pekka Jäkälä; Tobias Hartmann; Donald L Price; Michael K Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

6.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

7.  Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies.

Authors:  J E Duda; B I Giasson; Q Chen; T L Gur; H I Hurtig; M B Stern; S M Gollomp; H Ischiropoulos; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

Review 8.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Authors:  Michael J Volles; Peter T Lansbury
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

9.  Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.

Authors:  Wenxue Li; Christian Lesuisse; Yanqun Xu; Juan C Troncoso; Donald L Price; Michael K Lee
Journal:  J Neurosci       Date:  2004-08-18       Impact factor: 6.167

10.  Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.

Authors:  Michael K Lee; Wanda Stirling; Yanqun Xu; Xueying Xu; Dike Qui; Allen S Mandir; Ted M Dawson; Neal G Copeland; Nancy A Jenkins; Don L Price
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

View more
  133 in total

1.  Neurodegenerative disease: The stress of misfolding.

Authors:  Darran Yates
Journal:  Nat Rev Drug Discov       Date:  2012-04-30       Impact factor: 84.694

2.  The stress of misfolding.

Authors:  Darran Yates
Journal:  Nat Rev Neurosci       Date:  2012-04-04       Impact factor: 34.870

Review 3.  Impact of membrane curvature on amyloid aggregation.

Authors:  Mayu S Terakawa; Yuxi Lin; Misaki Kinoshita; Shingo Kanemura; Dai Itoh; Toshihiko Sugiki; Masaki Okumura; Ayyalusamy Ramamoorthy; Young-Ho Lee
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-04-28       Impact factor: 3.747

4.  Dissecting the Molecular Pathway Involved in PLK2 Kinase-mediated α-Synuclein-selective Autophagic Degradation.

Authors:  Manel Dahmene; Morgan Bérard; Abid Oueslati
Journal:  J Biol Chem       Date:  2017-01-30       Impact factor: 5.157

5.  Inhibition of Eukaryotic Initiation Factor 2 Alpha Phosphatase Reduces Tissue Damage and Improves Learning and Memory after Experimental Traumatic Brain Injury.

Authors:  Pramod K Dash; Michael J Hylin; Kimberly N Hood; Sara A Orsi; Jing Zhao; John B Redell; Andrey S Tsvetkov; Anthony N Moore
Journal:  J Neurotrauma       Date:  2015-07-20       Impact factor: 5.269

6.  Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1.

Authors:  Pamela Valdés; Gabriela Mercado; Rene L Vidal; Claudia Molina; Geoffrey Parsons; Felipe A Court; Alexis Martinez; Danny Galleguillos; Donna Armentano; Bernard L Schneider; Claudio Hetz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-21       Impact factor: 11.205

Review 7.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

Review 8.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 9.  The Role of the Protein Quality Control System in SBMA.

Authors:  Paola Rusmini; Valeria Crippa; Riccardo Cristofani; Carlo Rinaldi; Maria Elena Cicardi; Mariarita Galbiati; Serena Carra; Bilal Malik; Linda Greensmith; Angelo Poletti
Journal:  J Mol Neurosci       Date:  2015-11-14       Impact factor: 3.444

Review 10.  Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology.

Authors:  Sibylle E Eisbach; Tiago F Outeiro
Journal:  J Mol Med (Berl)       Date:  2013-04-25       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.